Abstract
Background Variability in antibody responses among individuals following vaccination is a universal phenomenon. Single-cell transcriptomics offers a potential avenue to understand the underlying mechanisms of these variations and improve our ability to evaluate and predict vaccine effectiveness.
Objective This study aimed to explore the potential of single-cell transcriptomic data in understanding the variability of antibody responses post-vaccination and its correlation with transcriptomic changes.
Methods Blood samples were collected from 124 individuals on day 21 post COVID-19 vaccination. These samples were categorized based on antibody titers (high, medium, low). On day 135, PBMCs from 27 donors underwent single-cell RNA sequencing to depict the transcriptome atlas.
Results Differentially expressed genes (DEGs) affecting antibody expression in various cell types were identified. We found that innate immunity, B cell, and T cell population each had a small set of common DEGs (MT-CO1, HLA-DQA2, FOSB, TXNIP, and JUN), and Macrophages and Th1 cells exhibited the largest number of DEGs. Pathway analysis highlighted the dominant role of the innate immune cell population in antibody differences among populations, with a significant impact from the interferon pathway. Furthermore, protein complexes analysis revealed that alterations in the ribosome complex, primarily regulated by DC cells, may play a crucial role in regulating antibody differences. Combining these findings with previous research we proposed a potential regulatory mechanism model of DC cells on B cell antibody production.
Conclusion While direct prediction of specific antibody levels using single-cell transcriptomic data remains technically and data-wise challenging, our study demonstrated the vast potential of single-cell transcriptomics in understanding the mechanisms underlying antibody responses induced by vaccines.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by National Natural Science Foundation of China (No.82161138018).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the BGI Institutional Review Board with approval number BGI-IRB 20161. Written informed consent for the storage, detection and potential research usage of the blood samples for further studies was obtained from the participants before enrollment.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
